Trastuzumab Deruxtecan
Daiichi Sankyo,AstraZeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rux,(-crux),(-trux)', 'trastuzumab deruxtecan']
trastuzumab deruxtecan elicits promising antitumor activity in her2+ mcrc #asco23 #crcsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.